AXE partners with Hylid Diagnostics for Biochip development
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Archer Materials Limited has announced a partnership with Hylid Diagnostics to develop a Biochip for at-home testing of chronic kidney disease. The collaboration will combine Archer's potassium sensing technology with Hylid's blood hemolysis sensor technology to create a prototype system. The first phase involves producing stand-alone hemolysis sensors that will integrate with Archer's Biochip to meet accuracy requirements for potassium measurement. This partnership aims to enhance patient outcomes through effective at-home testing solutions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Archer Materials Limited on 6ix
Story so far
Earlier from Archer Materials
- Appointment of Chief Executive Officer
- Improved Biochip Accuracy Paves Way for Human Blood Testing
- Precision spin state control for next-generation qubits
- Archer Granted Key Biochip Patent
- Breakthrough in Quantum Carbon Films for Qubit Realisation
Later from Archer Materials
- Quarterly Activity Report & Appendix 4C
- Archer partners with Paragraf for Biochip development
- Biochip integrates with readout circuitry on a silicon chip
- Archer Advances Quantum Technology
- TMR Sensor Functionality at Cryogenic Temperature
Follow Archer Materials into a list and get an email when it puts out news.
Follow Archer Materials